Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases

Pauli, Franziska Di; Mader, Simone; Rostásy, Kevin; Schanda, Kathrin; Bajer-Kornek, Barbara; Ehling, Rainer; Deisenhammer, Florian; Reindl, Markus; Berger, Thomas

doi:10.1016/j.clim.2010.11.013

Cited by 184 publications

(229 citation statements)

References 32 publications

Supporting

Mentioning

216

Contrasting

Unclassified

Order By: Relevance

“…1 The first demyelinating event with encephalopathy is termed as ADEM, which is classically monophasic disease and often recovers completely with corticosteroid, IVIG, or plasmapheresis theraphy. 3 Our patient was diagnosed as multiphasic pediatric ADEM with criteria including a new event of ADEM, which is a polyfocal, clinical CNS event with presumed inflammatory demyelinization, encephalopathy, and MRI findings including diffuse large T2/Flair hyperintensities in white matter and basal ganglia that occurred ≥3 months after the initial event and associated with new or reemergence of previous clinical and MRI findings. 4 Although the multiphasic ADEM criteria reported in 2007 included the condition of the occurrence of new attack 1 month after the interruption of steroid therapy, the revised 2012 multiphasic ADEM criteria did not mention timing of steroid therapy cessation as pertinent.…”

Section: Discussionmentioning

confidence: 99%

“…In contrast, persistence and fluctuations of MOG antibodies are associated with incomplete recovery of ADEM. Di Pauli et al 3 reported that the patients with full recovery of ADEM were accompanied by a decrease of MOG antibody levels. Follow-up studies showed that positivity of MOG antibodies continued between 4 and 69 months.…”

Section: Figurementioning

confidence: 99%

“…Patients with ADEM with incomplete recovery had a tendency to stay at positive titer with small fluctations. 3 Baumann et al 9 showed that 44% of patients with ADEM revealed positive MOG titers (median titer 1:80) during the follow-up period of 9 to 72 months.…”

Section: Figurementioning

confidence: 99%

See 2 more Smart Citations

Myelin Oligodendrocyte Glycoprotein Antibody Persistency in a Steroid-Dependent ADEM Case

Polat¹,

Yış²,

Karaoğlu³

et al. 2016

Pediatrics

View full text Add to dashboard Cite

Myelin oligodendrocyte glycoprotein (MOG) is a candidate target antigen in demyelinating central nervous system diseases, including acute disseminated encephalomyelitis (ADEM), neuromyelitis optica, and multiple sclerosis. It may give prognostic information regarding monophasic or recurrent course of the disease. MOG antibodies have been shown to be positive in high titers during the first episode of ADEM with rapidly decreasing to undetectable limits after recovery. However, persistent MOG antibodies are considered as a predicting factor for multiple sclerosis, optic neuritis relapses, and incomplete recovery of ADEM. Here we report a unique case with persistent MOG antibodies presented with multiphasic ADEM-like attacks. A 6-year-old girl was consulted with encephalopathy, gait disturbance, and oculomotor nerve palsy. Periventricular white matter lesions were seen on cranial magnetic resonance imaging studies. ADEM was diagnosed and treated with steroid. During follow-up, she experienced repeated episodes after steroid therapy termination. We were able to search MOG antibody at the ninth attack. The positivity of this antibody remained. It was thought to be associated with steroid-dependent course, and azathioprine and intravenous human immunoglobulin treatment were added. Patients with persistent MOG antibodies may benefit from addition of immunosuppressant agents, which may decrease the number of attacks.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Figurementioning

confidence: 99%

See 1 more Smart Citation

Myelin Oligodendrocyte Glycoprotein Antibody Persistency in a Steroid-Dependent ADEM Case

Polat¹,

Yış²,

Karaoğlu³

et al. 2016

Pediatrics

View full text Add to dashboard Cite

show abstract

“…At present, two European groups have proposed two live CBAs for anti-MOG antibody detection, which differ for the use of secondary antibodies, namely either anti-human total IgG [16] or anti-human IgG1 [15]. The methods likely differ in analytical sensitivity and specificity, which warrant appropriate studies.…”

Section: Future Perspectivesmentioning

confidence: 99%

A bridge between evidence-based laboratory diagnostics and research in neuroimmunology: why standardizations and guidelines matter

Franciotta

Uccelli

2017

Neurol Sci

View full text Add to dashboard Cite

“…A high proportion of patients with ADEM, especially children, are found to have antibodies directed toward myelin oligodendrocytes glycoprotein [63][64][65][66]. AHLE has been reported to occur in the context of several different viral infections, including cytomegalovirus, Epstein Barr virus, herpes simplex virus, the mumps virus, and the H1N1 virus [67][68][69][70][71].…”

Section: Ademmentioning

confidence: 99%

Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit

Geldern¹,

McPharlin

Becker

2012

Neurotherapeutics

View full text Add to dashboard Cite

This chapter will review the spectrum of immunemediated diseases that affect the nervous system and may result in an admission to the neurological intensive care unit. Immunomodulatory strategies to treat acute exacerbations of neurological diseases caused by aberrant immune responses are discussed, but strategies for long-term immunosuppression are not presented. The recommendations for therapeutic intervention are based on a synthesis of the literature, and include recommendations by the Cochrane Collaborative, the American Academy of Neurology, and other key organizations. References from recent publications are provided for the disorders and therapies in which randomized clinical trials and large evidenced-based reviews do not exist. The chapter concludes with a brief review of the mechanisms of action, dosing, and side effects of commonly used immunosuppressive strategies in the neurocritical care unit.

show abstract

Temporal dynamics of anti-MOG antibodies in CNS demyelinating diseases

Cited by 184 publications

References 32 publications

Myelin Oligodendrocyte Glycoprotein Antibody Persistency in a Steroid-Dependent ADEM Case

Myelin Oligodendrocyte Glycoprotein Antibody Persistency in a Steroid-Dependent ADEM Case

A bridge between evidence-based laboratory diagnostics and research in neuroimmunology: why standardizations and guidelines matter

Immune Mediated Diseases and Immune Modulation in the Neurocritical Care Unit

Contact Info

Product

Resources

About